Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

BACKGROUND: Targeted lung denervation (TLD) is a novel bronchoscopic therapy that disrupts parasympathetic pulmonary nerve input to the lung reducing clinical consequences of cholinergic hyperactivity. The AIRFLOW-1 study assessed safety and TLD dose in patients with moderate-to-severe, symptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Christophe, Pison, Pallav, L. Shah, Dirk-Jan, Slebos, Vincent, Ninane, Wim, Janssens, Thierry, Perez, Romain, Kessler, Gaetan, Deslee, Justin, L. Garner, Jorine, E. Hartman, Bruno, Degano, Anna, Mayr, Martin, Mayse, Alexander, D. Peterson, Arschang, Valipour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893728/
https://www.ncbi.nlm.nih.gov/pubmed/33608007
http://dx.doi.org/10.1186/s12931-021-01664-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893728/
https://www.ncbi.nlm.nih.gov/pubmed/33608007
http://dx.doi.org/10.1186/s12931-021-01664-5

Ejemplares similares